We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$474M
AUM Growth
+$192M
Cap. Flow
+$164M
Cap. Flow %
34.52%
Top 10 Hldgs %
94.15%
Holding
20
New
4
Increased
1
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$95.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$41.7M
3
MDCO
Medicines Co
MDCO
+$34.1M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$13.7M
5
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$10.3M

Top Sells

Rank Stock Value
1
A icon
Agilent Technologies
A
+$18.8M
2
BRLI
BIO-REFERENCE LABS INC-NEW-
BRLI
+$12.5M
3
BGMS
Bio Green Med Solution Inc
BGMS
+$263K

Sector Composition

Rank Sector Weight
1 Healthcare 91.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$106M 22.33%
12,850,000
– –
ABBV icon
2
AbbVie
ABBV
$443B
$92.5M 19.51%
+1,580,000
New +$95.5M
DGX icon
3
Quest Diagnostics
DGX
$25.7B
$59.6M 12.56%
775,000
– –
AMGN icon
4
Amgen
AMGN
$208B
$50.8M 10.72%
318,000
– –
AEGR
5
DELISTED
Aegerion Pharmaceuticals
AEGR
$42.9M 9.04%
+1,637,455
New +$41.7M
MDCO
6
DELISTED
Medicines Co
MDCO
$34M 7.18%
+1,215,100
New +$34.1M
MRK icon
7
Merck
MRK
$322B
$23M 4.85%
419,200
– –
AVDL
8
DELISTED
Avadel Pharmaceuticals
AVDL
$15.7M 3.32%
+875,000
New +$13.7M
SEEL
9
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$12.2M 2.57%
6
+5
+500% +$10.3M
RPRX
10
DELISTED
Repros Therapeutics Inc.
RPRX
$9.73M 2.05%
1,132,367
– –
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.6M 1.81%
360,000
– –
VVUS
12
DELISTED
Vivus Inc
VVUS
$6.33M 1.34%
257,394
– –
KIN
13
DELISTED
Kindred Biosciences, Inc.
KIN
$4.92M 1.04%
689,091
– –
AVEO
14
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$3.73M 0.79%
257,076
– –
ANIP icon
15
ANI Pharmaceuticals
ANIP
$1.8B
$1.94M 0.41%
31,000
– –
GYRE icon
16
Gyre Therapeutics
GYRE
$641M
$1.87M 0.39%
800
– –
CARM
17
DELISTED
Carisma Therapeutics
CARM
$368K 0.08%
2,060
– –
A icon
18
Agilent Technologies
A
$39.1B
– –
-460,000
Closed -$18.8M
BGMS
19
Bio Green Med Solution Inc
BGMS
$4.91M
– –
0
– -$263K
BRLI
20
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
– –
-390,270
Closed -$12.5M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sarissa Capital Management held 20 positions worth $474M, up 68% from $283M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Sarissa Capital Management deployed $164M of net new capital in Q1 2015, opening 4 new positions and adding to 1 existing holding. Its largest new stake was AbbVie: 1,580,000 shares worth $92.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier.

On the sell side, the most notable exit was Agilent Technologies, an estimated $18.8M sold.

  • Sarissa Capital Management's largest Q1 2015 buy was AbbVie: 1,580,000 shares worth $92.5M.
  • Sarissa Capital Management added most to Seelos Therapeutics, Inc. Common Stock in Q1 2015, an estimated $10.3M increase.
  • Sarissa Capital Management fully exited Agilent Technologies in Q1 2015, selling an estimated $18.8M.
  • Sarissa Capital Management's ten largest holdings make up 94% of its $474M portfolio in Q1 2015.
  • Sarissa Capital Management opened 4 new positions and closed 2 in Q1 2015.
  • Sarissa Capital Management's portfolio value rose 68% quarter-over-quarter to $474M.

Based on Sarissa Capital Management's 13F filing for Q1 2015, filed 15 May 2015.